From:	Ehud Barak <ehbarak1@gmail.com>
To:	Goryanin Dr. Igor <goryanin@gmail.com> Andrew Intrater <aintrater@columbusnova.com>
CC:	
Date:	Sun, 12/14/2014 11:02:28 PM
Subject:	Fwd: Our IP and 5 patents BrainStem Biotec

Dear Igor
Pl find attached more scientific material re Prof. Slavin proposals.
Read it and tell us what you think.
In few minutes I'll send you an Introduction email to Prof. Slavin.
Pl take the initiative and contact him afterwards. He asked for no NDA. But I suggest that we won't use his material improperly anyhow.
Looking forward
Best
Ehud Barak

Sent from my iPhone

Begin forwarded message:

> **From:** "Prof. Shimon Slavin" <slavinmd@gmail.com>
> **Date:** December 4, 2014 at 16:58:03 GMT+2
> **To:** Ehud Barak <ehbarak1@gmail.com>
> **Cc:** Chaya Brodie <nscha@neuro.hfh.edu>, Aharon Feurstein <nanom@bezeqint.net>
> **Subject: Fwd: Our IP and 5 patents BrainStem Biotec**
>
> Dear Ehud,
>
> As you recall, we sent you our proposal of BrainStem Biotec, a company committed for treatment of neurological and malignant disorders of the central nervous system. The IP consists of 5 patent applications [and more in the pipeline]. Enclosed please find the patent applications that represent the scientific basis of our proposal. This will give a serious scientist like Bob Weinberg an opportunity to evaluate our scientific platform for regenerative medicine. Please bear in mind that he may have conflict of interests because he is involved in the field.
>
> I also enclosed earlier a preliminary proposal for a new company for treatment of type 1 and type 2 diabetes mellitus. We are now in the process of filing the IPs to the patent office, so we prefer not to disclose it at this point since these new approaches are not yet protected.
>
> We also included a proposal for an existing company focusing on the establishment of a bank for the collection, preparation and long-term cryopreservation of placenta & cord tissue derived mesenchymal stromal cells (MSCs). These companies own some proprietary technology that is now being submitted as patent applications. Basically, we have identified different sub-populations of MSCs with different functions, which enable us to isolate and store cells with multi-potent properties suitable for the treatment of specific clinical indications such as diabetes, as well as diseases of the central nervous system, the heart, kidney and the skeletal system including repair of cartilage and bones. In addition, we identified subpopulations that are more suitable for the treatment

of different tumors by exerting anti-tumor effects in addition to their ability of targeted delivery of different anti-tumor agents including miRNA and lncRNAs.

You are welcome to send Prof Weinberg all the 3 proposals. Please advise him to look at the IPs developed by BrainStem Biotec [5 patent applications] that can give him an idea of the technologies and approaches we have developed. We are sorry that at this stage we cannot send unprotected information for the two other companies or the additional patents for BrainStem Biotec currently in the pipelines, and I am sure he will understand it.

What I would suggest practically speaking is the following text:

Dear Prof. Weinberg,

Please see attached a proposal for the development of three companies (that can be clustered under one umbrella) for cell-based regenerative medicine using MSCs differentiated to various cell types such as cells expressing phenotypes of glial cells and neurons which is supported by 5 international patents and some in the pipeline; insulin secreting cells and the identification of subpopulations of stem cells that are suitable for the treatment of specific pathological conditions. The IPs of the latters are currently being submitted as patent applications. In addition, we have developed novel technologies for the treatment of brain tumors (both primary and metastatic). The basic scientific rational was already confirmed and validated using human cells in different pre-clinical animal models and also clinically in some preliminary studies.

Your scientific input will help us decide investment policies.

Thanks for trying to help.

Shimon Slavin, M.D.
Professor of Medicine
Scientific & Medical Director
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Weizman Center, 14 Weizman Street, Tel Aviv 64239, ISRAEL

Tel: +972-77 777 9255
Fax: +972-77 777 9247
Email: slavin@CTCIcenter.com
Private Email: slavinMD@gmail.com
Website: http://www.CTCIcenter.com

Begin forwarded message:

52911 WO2010144698 A3.pdf
51968 WO2012023132 A1.pdf
55797 WO2013124817 A2.pdf
55798 WO2013124816 A2.pdf
55799 WO2013124815 A2.pdf